Resources
114 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/7/2019 (updated 3/25/2024)
The Adopting a Shared Framework for Community Collaboration webinar addresses new questions and comments about the development of a shared public health framework, strategic planning, consortium partners, and opioid use disorder treatment.
Posted 10/7/2019 (updated 3/25/2024)
An Introduction to Harm Reduction Webinar Presentation and Materials
Posted 11/19/2019 (updated 3/25/2024)
Although typically delivered via intramuscular or intravenous injection, naloxone may be delivered via intranasal spray device.
Posted 1/5/2022 (updated 3/26/2024)
This brief reviews the history, harms, pathways and trends that treat children as if they were adults
Posted 2/9/2022 (updated 3/26/2024)
Summary of innovation abstracts that were presented at the National Academy of Medicine’s recent Stigma of Addiction Summit.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 8/8/2023 (updated 3/26/2024)
This webinar is an invaluable opportunity for health care professionals, policymakers, researchers, and anyone else interested in mental health and substance use interventions to learn about the latest research and innovative approaches in the field.
Posted 3/2/2022 (updated 3/26/2024)
In this webinar you will hear from Fair Chance employers and advocates. They will offer insights into the benefits of fair chance employment (for formerly incarcerated or otherwise justice impacted people) and outline opportunities to take steps toward becoming a Fair Chance employer.
Posted 3/3/2022 (updated 3/26/2024)
The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programs, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).
Posted 9/8/2023 (updated 3/27/2024)
With a large number of individuals incarcerated in the United States, there is a growing problem with the effects it can have on a person's health. The National Institute for Health Care Management (NIHCM) has provided an infographic detailing the effects, health conditions, and growing inequality people live with while incarcerated.